Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study

Table 3

𝑁=28		Mean	Std. deviation	Std. error mean	𝑃 value
Physical health	T1	25.9	19.7	4.8	.191
	T2	27.4	22.9	5.6
Role limitation (physical)	T1	25.0	35.4	8.6	.173
	T2	32.4	35.1	8.5
Role limitation (emotional)	T1	68.6	39.9	9.7	.985
	T2	62.7	42.3	10.3
Pain	T1	68.2	28.9	7.0	.963
	T2	82.3	23.4	5.7
Emotional well-being	T1	77.6	20.2	4.9	.761
	T2	72.7	13.2	3.2
Energy	T1	47.5	22.5	5.5	.740
	T2	47.3	18.0	4.4
Health perception	T1	36.2	18.2	4.4	.041
	T2	37.4	15.6	3.8
Social function	T1	54.9	12.9	3.1	.631
	T2	58.8	12.3	3.0
Cognitive function	T1	66.5	26.9	6.5	.669
	T2	76.5	19.0	4.6
Health distress	T1	67.1	21.2	5.1	.517
	T2	69.4	21.4	5.2
Sexual function	T1	44.6	31.3	7.6	.203
	T2	51.0	32.1	7.8
Change in health	T1	27.9	26.3	6.4	.409
	T2	36.8	28.1	6.8
Sexual satisfaction	T1	35.3	36.5	8.9	.394
	T2	44.1	37.0	9.0
Overall QoL	T1	58.2	13.2	3.2	.725
	T2	57.7	12.0	2.9
MS QoL54 (physical)	T1	44.3	15.3	3.7	.446
	T2	48.4	15.4	3.7
MS QoL54 (mental)	T1	68.8	20.6	5.0	.863
	T2	67.7	17.5	4.2
MS QoL54 (total)	T1	113.1	33.9	8.2	.955
	T2	116.1	30.9	7.5